🔓 Unlock the full profile of Marshall Fordyce (Vera Therapeutics, Inc.), including verified contact details, financial insights, and professional associations.
See Marshall Fordyce Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: mar*****@ver******.com
Mobile: 75216*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Marshall Fordyce is the Founder and Chief Executive Officer of Vera Therapeutics, Inc., a biopharmaceutical company established in 2016, specializing in advancing therapies for patients with severe autoimmune and rare diseases.
- Under Fordyce's leadership, Vera Therapeutics, Inc. has made significant progress in developing innovative treatments, contributing to research and advancements in the field of immunology.
- Before founding Vera Therapeutics, Fordyce served as an Entrepreneur In Residence at Kleiner Perkins from July 2016 to February 2017, leveraging experience to enhance startup initiatives in the healthcare sector.
- Fordyce held the position of Senior Director of Clinical Research at Gilead Sciences for a brief period in early 2016, focusing on advancing clinical programs.
- Fordyce gained valuable research experience as a Research Fellow and Instructor at The Rockefeller University from 2009 to 2011, contributing to significant scientific discoveries in the field of infectious diseases.
- While completing an Infectious Disease Fellowship at Columbia University Vagelos College of Physicians and Surgeons from 2008 to 2010, Fordyce developed an expertise in treating complex infectious diseases.
- Vera Therapeutics, Inc. is publicly traded on the NASDAQ under the symbol “VERA,” indicating its success in attracting investment and support from the public market.
- As of recent reports, Vera Therapeutics, Inc. has achieved a market capitalization of approximately $1.4 billion, highlighting its economic impact and potential for future growth.
- The company has experienced significant growth, with a 24-month headcount increase of approximately 77%, reflecting its expanding operational capabilities and commitment to innovation.